NCT02235558View on ClinicalTrials.gov

Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

February 1, 2013

Primary Completion Date

March 21, 2016

Study Completion Date

March 21, 2016

Conditions
Ischemic Stroke
Interventions
DRUG

Verapamil

Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.

Trial Locations (1)

40536

University of Kentucky Deparment of Neurosurgery, UK Chandler Hospital, Lexington

All Listed Sponsors
lead

Justin Fraser

OTHER

NCT02235558 - Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter